Antibiotic

Algae Products Market is Expected to Observe Phenomenal Growth by 2028 | Key Players - MCPI, Karagen Indonesia, Shemberg & Matsumaeya: Radiant Insights, Inc.

Retrieved on: 
Wednesday, October 16, 2019
Life sciences, Articles, Health, Pharmacy, Biotechnology, Antimicrobial, Biocides, Algae, Microorganism, Antibiotic, Biopharmaceutical, Pharmaceutical industry

SAN FRANCISCO, Oct. 16, 2019 /PRNewswire/ -- The Global Algae Products Market is expected to grow at a substantial CAGR in the years to come.

Key Points: 
  • SAN FRANCISCO, Oct. 16, 2019 /PRNewswire/ -- The Global Algae Products Market is expected to grow at a substantial CAGR in the years to come.
  • As such, algae products are being actively used in pharmaceutical sector to produce anti-viral, anti-bacterial, and anti-microbial medicines, drugs to treat cancer, human therapeutic proteins, and neuroprotective products.
  • It covers the sales volume, price, revenue, gross margin, historical growth and future perspectives in the Algae Products market.
  • Access 118 page research report with TOC on "Global Algae Products Market" available with Radiant Insights, Inc. @: https://www.radiantinsights.com/research/2013-2028-report-on-global-alga...
    Leading players of Algae Products including:

Nabriva to Present Data at the CHEST Annual Meeting Demonstrating the Safety and Efficacy of Newly FDA-Approved XENLETA (lefamulin) for the Treatment of Community-Acquired Bacterial Pneumonia (CABP)

Retrieved on: 
Tuesday, October 15, 2019
Chemical compounds, Respiratory diseases, Medical specialties, Infectious diseases, RTT, Fluoroquinolone antibiotics, Cyclopropanes, Moxifloxacin, Pneumonia, Antibiotic, Lower respiratory tract infection, Bacterial pneumonia

In addition to efficacy overall, analyses stratified by Pneumonia Outcomes Research Team (PORT) Risk Class, from both pooled and individual trials, were presented.

Key Points: 
  • In addition to efficacy overall, analyses stratified by Pneumonia Outcomes Research Team (PORT) Risk Class, from both pooled and individual trials, were presented.
  • Pooled data from the LEAP 1 and LEAP showed similar safety and tolerability profiles for lefamulin and moxifloxacin.
  • Community-acquired bacterial pneumonia (CABP) is a lung infection and the most common type of pneumonia.
  • Nabriva Therapeutics received U.S. Food and Drug Administration approval for XENLETA (lefamulin), the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia (CABP).

Scientists from NUST MISIS Create a Material for Implants Which Destroys up to 98% of Bacteria

Retrieved on: 
Monday, October 14, 2019
Medical specialties, Infectious diseases, Medicine, Bacterial diseases, Bacteriology, Antibiotic, Pathogenic bacteria, Bacteria, Infection, RTT, Antimicrobial resistance

Due to the platinum and iron nanoparticles in the composition, the material is able to kill up to 98% of bacteria within 12 hours after installation.

Key Points: 
  • Due to the platinum and iron nanoparticles in the composition, the material is able to kill up to 98% of bacteria within 12 hours after installation.
  • Bacterial infection occurs in 1-4% of cases after a planned surgery when installing implants, and in the cases of complex fractures, the probability of its occurrence reaches 30%.
  • With this treatment, pathogenic bacteria very quickly develop resistance to antibiotics, moreover, many people have a severe allergy to medications.
  • Another promising application of the developed material may be the creation of filters for water purification.

Scientists from NUST MISIS Create a Material for Implants Which Destroys up to 98% of Bacteria

Retrieved on: 
Monday, October 14, 2019
Medical specialties, Infectious diseases, Medicine, Bacterial diseases, Bacteriology, Antibiotic, Pathogenic bacteria, Bacteria, Infection, RTT, Antimicrobial resistance

Due to the platinum and iron nanoparticles in the composition, the material is able to kill up to 98% of bacteria within 12 hours after installation.

Key Points: 
  • Due to the platinum and iron nanoparticles in the composition, the material is able to kill up to 98% of bacteria within 12 hours after installation.
  • Bacterial infection occurs in 1-4% of cases after a planned surgery when installing implants, and in the cases of complex fractures, the probability of its occurrence reaches 30%.
  • With this treatment, pathogenic bacteria very quickly develop resistance to antibiotics, moreover, many people have a severe allergy to medications.
  • Another promising application of the developed material may be the creation of filters for water purification.

Armata Pharmaceuticals Expands Board of Directors with the Appointment of Research and Development Veteran Todd C. Peterson, Ph.D.

Retrieved on: 
Thursday, October 10, 2019
Articles, Health, Bacteriophage, Antibiotic, Antimicrobial resistance, Medicine, Bacteriophages

"Todd is a proven leader with a track record of successfully driving research and development initiatives across a broad range of therapeutic indications," said Todd R. Patrick, Chief Executive Officer of Armata.

Key Points: 
  • "Todd is a proven leader with a track record of successfully driving research and development initiatives across a broad range of therapeutic indications," said Todd R. Patrick, Chief Executive Officer of Armata.
  • "I am excited to join Armata's Board to help maximize the potential of the company's proprietary phage screening, identification and manufacturing capabilities," said Dr. Peterson.
  • "With the rise of antibiotic resistance globally, common infections are becoming more difficult to treat, and new solutions are badly needed.
  • Armata is committed to advancing phage with drug development expertise that spans bench to clinic including in-house phage specific GMP manufacturing.

Notice of Results

Retrieved on: 
Thursday, October 10, 2019
Antibiotic

Oxford, UK, and Cambridge, MA, US, 10 October 2019 Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) a leader in new mechanism antibiotic innovation, will announce its financial results for the second quarter and half year ended 31 July 2019 on 11 October 2019.

Key Points: 
  • Oxford, UK, and Cambridge, MA, US, 10 October 2019 Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) a leader in new mechanism antibiotic innovation, will announce its financial results for the second quarter and half year ended 31 July 2019 on 11 October 2019.
  • Summit will host a conference call the same day at 1:00pm BST / 8:00am EDT.
  • Conference call information will be included in the second quarter and half year results press release, and a replay of the call will also be available through the Companys website, www.summitplc.com .
  • Our new mechanism antibiotics are designed to become the new standards of care for the benefit of patients and create value for payors and healthcare providers.

Adaptive Phage Therapeutics Completes Oversubscribed Strategic Financing

Retrieved on: 
Friday, October 4, 2019
Biotechnology, Health, Finance, Pharmaceutical, Professional services, Other Science, Research, General Health, Science, Clinical trials, Health, Medicine, Medical specialties, Bacteriophages, Pharmaceuticals policy, Phage therapy, Therapy, Bacteriophage, Antimicrobial resistance, Multiple drug resistance, Antibiotic, Drug resistance

Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company founded to provide an effective therapeutic response to the global rise of multi-drug resistant (MDR) pathogenic bacteria, today announced that it has closed an oversubscribed, non-brokered financing, raising approximately $7 million in proceeds.

Key Points: 
  • Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company founded to provide an effective therapeutic response to the global rise of multi-drug resistant (MDR) pathogenic bacteria, today announced that it has closed an oversubscribed, non-brokered financing, raising approximately $7 million in proceeds.
  • Phage therapy is emerging as the most promising alternative to dealing with the crisis of antibiotic resistance in bacterial infection, said Greg Merril, Chief Executive Officer and co-founder of APT.
  • The high level of interest from strategic and financial investors in support of our expanding clinical pipeline validates the potential phage therapy holds for patients.
  • Adaptive Phage Therapeutics, Inc. (APT) is a clinical-stage company founded to provide an effective therapeutic response to the global rise of multi-drug resistant (MDR) pathogenic bacteria.

Entasis Therapeutics Announces Multiple Presentations at ID Week 2019

Retrieved on: 
Thursday, October 3, 2019
Bacteria, Organic compounds, Chemistry, Infections with a predominantly sexual mode of transmission, Antibiotic, Zoliflodacin, Infection, Neisseria, Sulbactam, Entasis, Pathogen

"ID Week represents an important opportunity for academia and industry to converge to discuss the latest advancements in tackling infectious diseases.

Key Points: 
  • "ID Week represents an important opportunity for academia and industry to converge to discuss the latest advancements in tackling infectious diseases.
  • Details of the Presentations are as follows:
    Panel Presentation: Were Part of the Problem: How ID Killed Antibiotic Development
    Timing: Thursday, October 3rd at 10:30 11:45 a.m.
  • Entasis pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam (targetingAcinetobacter baumanniiinfections), zoliflodacin (targetingNeisseria gonorrhoeae), and ETX0282CPDP (targetingEnterobacteriaceaeinfections).
  • These forward-looking statements are based on Entasis expectations and assumptions as of the date of this press release.

Acurx's Novel Lead Antibiotic Candidate Presented at Two Prominent International Scientific Conferences

Retrieved on: 
Thursday, October 3, 2019
Microorganisms, Microbiology, Bacteriology, Clostridiaceae, Gram-positive bacteria, Environmental microbiology, Clostridioides, Antibiotic, -bacter, Gut flora, Bacteroidetes, Infection

This differential was especially pronounced among the phyla, Bacteroidetes and Firmicutes which generally comprise up to 90% of the healthy human gut microbiome."

Key Points: 
  • This differential was especially pronounced among the phyla, Bacteroidetes and Firmicutes which generally comprise up to 90% of the healthy human gut microbiome."
  • The abstract will be published as an online supplement to Open Forum Infectious Diseases (OFID), the Open Access Journal from IDSA.
  • Complete study results are in preparation for submission to a scientific journal.
  • In a poster entitled "Time-kill Kinetics of the Novel Antibacterial Agent ACX-362E against Clostridioides difficile" results were presented demonstrating rapid bacterial killing and potent bactericidal activity.

ContraFect Announces Plan for a Single Phase 3 Superiority Design Study of Exebacase Following Successful End-of-Phase 2 Meeting with FDA

Retrieved on: 
Wednesday, October 2, 2019
Infectious diseases, Medical specialties, Medicine, Bacterial diseases, Healthcare-associated infections, Antibiotic-resistant bacteria, Methicillin-resistant Staphylococcus aureus, Pathovars, Staphylococcaceae, Antibiotic, Bacteremia, Brilacidin

Exebacase is the first product candidate of its class and represents the potential of direct lytic agents as an entirely new treatment modality.

Key Points: 
  • Exebacase is the first product candidate of its class and represents the potential of direct lytic agents as an entirely new treatment modality.
  • Exebacase could be the first agent ever to demonstrate superior efficacy compared to traditional antibiotics in treating patients with complicated MRSA bacteremia in a Phase 3 study.
  • We appreciate the efforts of the FDA in working with us to advance exebacase as a streamlined development program.
  • Patients entering the Phase 3 study will be randomized 2:1 to either exebacase or placebo, with all patients receiving standard-of-care antibiotics.